Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
Provider: Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

TAKARA BIO INC Amends Consolidated Mid-year Outlook for FY 2014

Tuesday, 30 Jul 2013 02:00am EDT 

TAKARA BIO INC announced that it has raised consolidated mid-year outlook for revenue from JPY 9,818 million to JPY 10,300 million, but lowered the outlook for operating profit from JPY 427 million to JPY 300 million, ordinary profit from JPY 459 million to JPY 310 million, net profit from JPY 249 million to JPY 130 million, earning per share from JPY 2.2 to 1.14 for the fiscal year ending March 2014. The negative outlook for profit is mainly due increase of research and development cost. 

Company Quote

24 Apr 2015